Low endogenous testosterone level is associated with high-risk prostate-specific antigen level in men with prostate cancer disease

Collins Amadi; Ehimen P. Odum; Benjamin M. Aleme

doi:10.18203/2349-2902.isj20181581

Authors

Collins Amadi Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Ehimen P. Odum Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
Benjamin M. Aleme Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

DOI:

https://doi.org/10.18203/2349-2902.isj20181581

Keywords:

Hypogonadism, PSA, Prostate-specific antigen, Prostate cancer, Testosterone

Abstract

Background: Low serum testosterone levels is hypothesized to predict adverse outcomes in prostate cancer patients. This study was structured to investigate this hypothesis using high-risk serum prostate-specific antigen as a marker of adverse outcome of the disease.

Methods: This was a retrospective analysis of serum total testosterone (TT) and total prostate-specific antigen (PSA) records of prostate cancer patients in a tertiary hospital in Nigeria. Records of age, serum TT, and serum PSA test results from 1st January 2008 to 31st December 2017 were acquired from laboratory and medical records and analyzed with SPSS software version 20.

Results: The records of 450 men with prostate cancer were recruited for the study. The majority (56.7%) of the study cohorts were between 70 to 79 years of age. Hypogonadism was observed in 34.7% of the study cohort. The hypogonadal patients had higher PSA values compared to the eugonadal patients (p<0.001). Lower testosterone values were observed in patients with high-risk PSA levels (p<0.001). Strong significant negative correlations were observed between total PSA and endogenous testosterone within the overall study cohort (r= -0.792; p< 0.001), the hypogonadal group (r= -0.615; p < 0.001), and among the high-risk PSA group (r= -0.632; p< 0.001).

Conclusions: The findings of this study suggest low, rather than high, endogenous testosterone in prostate cancer disease is associated with high-risk PSA levels which implies adverse outcome in prostate cancer patients. However, further studies are warranted to confirm this association.

Metrics

Metrics Loading ...

Author Biography

Collins Amadi, Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

Consultant Chemical Pathologist

References

Huggins C, Hodges CV. Studies on prostate cancer, The effect of castration, of estrogen and of androgen injection on serum phosphate in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.

Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209-23.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009;56(1):48-56.

Etawo US, Ekeke ON, Miaba AB. Prospective study of sex hormones levels among prostate cancer patients attending University of Port Harcourt Teaching Hospital clinic. Nig Health J. 2012; 12(2): 39-42.

Klap J, Schmid M, Loughlin KR. The relationship between total testosterone levels and prostate cancer: A review of the continuing controversy. J Urol. 2015;193(2):403-13.

Alsharef MM, Kahie A, Conradie M, Goad EA, Fourie T. Association between low serum free testosterone and adverse prognostic factors in men diagnosed with prostate cancer in Kwazulu-Natal. S Afr J Surg. 2012;50(2):40-2.

Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urol. 2008;72(6):1240-5.

Botto H, Neuzillet Y, Labret T, Camparo P, Molinie V, Raynaud JP. High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol. 2011;186(4):1400-5.

Garcia-Cruz E, Piqueras M, Huguet J, Peril L, Izquierdo L, Musquera M, et al. Low testosterone levels are related to poor prognostic factors in men with prostate cancer. BJU Int. 2012; 110(11B): E541-E6.

Schatzl G, Maddersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, et al. High-grade prostate is associated with low testosterone levels. Prostate. 2001;47(1);52-8.

Morgentaler A. Turning conventional wisdom upside-down: Low serum testosterone and high-risk prostate cancer. Cancer. 2011;117(17):3885-8.

Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007;51(2):375-80.

Isom-Batze G, Bianco FJ Jr, Kattam MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage at clinically localized prostate cancer. J Urol. 2003;173(6):1935-7.

San Francisco IF, Regan MM, DeWolf WC, Olumi AF. Low age-adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol. 2006; 175(4): 1341-6.

Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high-grade prostate cancer. J Urol. 2000;163(3): 824-7.

Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, et al. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett. 2017;13(3):1949-57.

Shin BS, Hwang EC, Im CM, Kim S, Jung S, Kang TW, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of Korean men. Korean J Urol. 2010;51(12);819-23.

Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Beman N, et al. Testosterone dose-response relationship in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6);E1172- E81.

Martin NE, Mucci LA, Loda A, Depinho RA. Prognostic determinants in prostate cancer. Cancer J. 2011;17(6):429-37.

Loeb S, Folkvaljon Y, Damber J, Alukal J, Lambe M, Stattin P. Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol. 2017;35(13):1430-6.